MF-59

BIOLOGICAL5 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), National Taiwan University Hospital

Conditions

Antibody ResponseCytomegalovirus InfectionsInfluenzaParvovirus B19 Infection

Phase 1

H5 Adult - Chiron Study of Bird Flu Vaccine

CompletedNCT00280033

National Institute of Allergy and Infectious Diseases (NIAID)Influenza

Start: 2006-02-28End: 2006-11-30Updated: 2013-09-13

B-19 Parvovirus Vaccine Study

TerminatedNCT00379938

National Institute of Allergy and Infectious Diseases (NIAID)Parvovirus B19 Infection

Start: 2006-08-31End: 2008-10-31Updated: 2011-08-15

Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59

CompletedNCT00912496

National Institute of Allergy and Infectious Diseases (NIAID)Influenza

Start: 2010-06-30End: 2011-12-31Updated: 2013-05-14

Phase 2

gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

CompletedNCT00133497

National Institute of Allergy and Infectious Diseases (NIAID)Cytomegalovirus Infections

Start: 2006-06-30End: 2013-06-30Updated: 2017-07-06

Unknown Phase

Serological Responses to Adjuvanted Versus Non-adjuvanted Influenza Vaccines Among People With HIV: a Randomized Clinical Trial

Not yet recruitingNCT07126652

National Taiwan University HospitalAntibody Response

Start: 2025-10-01End: 2027-12-31Target: 300Updated: 2025-08-17

Related Papers

Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.

2024-08-0148 citations

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults.

2008-03-01164 citations